目的 分析啟東市人民醫(yī)院2016年活血化瘀類中成藥用藥情況，為臨床安全用藥提供指導(dǎo)。方法 收集啟東市人民醫(yī)院2016年活血化瘀類中成藥的出庫數(shù)據(jù)以及上報的不良反應(yīng)報告。對藥品種類、銷售金額、用藥頻度（DDDs）、日均費用（DDC）、排序比（B/A）和不良反應(yīng)的類型、科室分布進(jìn)行統(tǒng)計、排序和分析。結(jié)果 2016年啟東市人民醫(yī)院活血化瘀類中成藥分布科室以心內(nèi)科、神經(jīng)內(nèi)一科和神經(jīng)內(nèi)二科為主，分別占26.11%、16.91%、15.13%。活血化瘀類中成藥銷售額最高的是舒血寧注射液，DDDs最高的是血府逐瘀片，DDC最高的是丹紅注射液，大部分藥品的B/A值偏離1，表明市場份額和用藥選擇一致性較差。34例（2.52%）發(fā)生不良反應(yīng)，注射劑有27例，非注射劑7例。結(jié)論 啟東市人民醫(yī)院活血化瘀類中成藥臨床應(yīng)用仍存在一定的不合理情況，需要采取一些干預(yù)措施。

Objective To analyze the clinical application of blood circulation category of Chinese patent medicine in Qidong People's Hospital in 2016, in order to provide guidance for clinical medication. Methods The database about blood circulation category of Chinese patent medicine was collected in Qidong People's Hospital in 2016, and the adverse drug reaction reports were also collected. The drug varieties, sales amount, defined daily doses (DDDs), average daily cost (DDC), sorting ratio (B/A), the types and department distribution of adverse reaction were analyzed and sorted. Results The three most distribution departments of blood circulation category of Chinese patent medicine were cardiology department, 1st neurology department and 2nd neurology department in Qidong People's Hospital in 2016, accounted for 26.11%, 16.91% and 15.13%, respectively. The drug with the highest sales amount was Shuxuening Injection. DDDs of Xuefu Zhuyu Tablets were the highest. DDC of Danhong Injection was the highest. The B/A values of most drugs were far from 1, showing poor consistency between market share and drug choice. There were 34 cases (2.52%) adverse reactions, including 27 cases of injection and 7 cases of no-injection. Conclusion There are still some unreasonable situations of blood circulation category of Chinese patent medicine in Qidong People's Hospital in 2016, which needs to take some intervention measures.